1. Smolen, JS, Aletaha, D, McInnes, IB. Rheumatoid arthritis. Lancet 2016; 388: 2023–2038.
Google Scholar | Crossref | Medline2. Kuo, CF, Luo, SF, See, LC, et al. Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan. Rheumatol Int 2013; 33: 355–360.
Google Scholar | Crossref | Medline3. Humphreys, JH, Verstappen, SM, Hyrich, KL, et al. The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. Ann Rheum Dis 2013; 72: 1315–1320.
Google Scholar | Crossref | Medline | ISI4. Hunter, TM, Boytsov, NN, Zhang, X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int 2017; 37: 1551–1557.
Google Scholar | Crossref | Medline5. Crowson, CS, Matteson, EL, Myasoedova, E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63: 633–639.
Google Scholar | Crossref | Medline6. Radner, H, Lesperance, T, Accortt, NA, et al. Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res (Hoboken) 2017; 69: 1510–1518.
Google Scholar | Crossref | Medline7. Solomon, DH, Karlson, EW, Rimm, EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303–1307.
Google Scholar | Crossref | Medline | ISI8. Castañeda, S, Nurmohamed, MT, Gonzalez-Gay, MA. Cardiovascular disease in inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol 2016; 30: 851–869.
Google Scholar | Crossref | Medline9. Avina-Zubieta, JA, Choi, HK, Sadatsafavi, M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690–1697.
Google Scholar | Crossref | Medline10. Avina-Zubieta, JA, Thomas, J, Sadatsafavi, M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012; 71: 1524–1529.
Google Scholar | Crossref | Medline | ISI11. Jagpal, A, Navarro-Millán, I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatol 2018; 2: 10.
Google Scholar | Crossref | Medline12. Crowson, CS, Rollefstad, S, Ikdahl, E, et al; A trans-atlantic cardiovascular consortium for rheumatoid arthritis (ATACC-RA). Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2018; 77: 48–54.
Google Scholar | Crossref | Medline13. Gonzalez, A, Maradit Kremers, H, Crowson, CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008; 67: 64–69.
Google Scholar | Crossref | Medline | ISI14. Choy, E, Ganeshalingam, K, Semb, AG, et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 2014; 53: 2143–2154.
Google Scholar | Crossref | Medline | ISI15. Zhang, J, Chen, L, Delzell, E, et al. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2014; 73: 1301–1308.
Google Scholar | Crossref | Medline | ISI16. Gonzalez-Gay, MA, Gonzalez-Juanatey, C, Lopez-Diaz, MJ, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 125–132.
Google Scholar | Crossref | Medline17. Goodson, NJ, Symmons, DP, Scott, DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005; 52: 2293–2299.
Google Scholar | Crossref | Medline18. Tomasson, G, Aspelund, T, Jonsson, T, et al. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2010; 69: 1649–1654.
Google Scholar | Crossref | Medline19. López-Longo, FJ, Oliver-Miñarro, D, de la Torre, I, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009; 61: 419–424.
Google Scholar | Crossref | Medline20. Hansson, GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–1695.
Google Scholar | Crossref | Medline | ISI21. Peters, MJ, Symmons, DP, McCarey, D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325–331.
Google Scholar | Crossref | Medline | ISI22. Roubille, C, Richer, V, Starnino, T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 480–489.
Google Scholar | Crossref | Medline | ISI23. Solomon, A, Tsang, L, Woodiwiss, AJ, et al. Cardiovascular disease risk amongst African black patients with rheumatoid arthritis: the need for population specific stratification. Biomed Res Int 2014; 2014: 826095.
Google Scholar | Crossref | Medline24. National Health Insurance Annual Report 2014-2015 . National Health Insurance Administration, Ministry of Health and Welfare, Taiwan, R.O.C.
Google Scholar25. Arnett, FC, Edworthy, SM, Bloch, DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–324.
Google Scholar | Crossref | Medline26. Aletaha, D, Neogi, T, Silman, AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569–2581.
Google Scholar | Crossref | Medline27. Hicks, KA, Tcheng, JE, Bozkurt, B, et al; ACC/AHA Task Force on Clinical Data Standards Members . 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association task force on clinical data standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Nucl Cardiol 2015; 22: 1041–1144.
Google Scholar | Medline28. Dehmer, GJ, Badhwar, V, Bermudez, EA, et al. 2020 AHA/ACC key data elements and definitions for coronary revascularization: a report of the American College of Cardiology/American Heart Association task force on clinical data standards (Writing Committee to Develop Clinical Data Standards for Coronary Revascularization). J Am Coll Cardiol 2020; 75: 1975–2088.
Google Scholar | Medline29. Martin-Martinez, MA, Castañeda, S, Sanchez-Alonso, F, et al; CARMA Project Collaborative Group . Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study-results at 5 years of follow-up. Rheumatology (Oxford). 2021; 60: 2906–2915.
Google Scholar | Crossref | Medline30. López-Mejías, R, Castañeda, S, González-Juanatey, C, et al. Cardiovascular risk assessment in patients with rheumatoid arthritis: the relevance of clinical, genetic and serological markers. Autoimmun Rev 2016; 15: 1013–1030.
Google Scholar | Crossref | Medline31. Turesson, C, Schaid, DJ, Weyand, CM, et al. The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R1386–R1393.
Google Scholar | Crossref | Medline32. Liu, SC, Chang, TY, Lee, YJ, et al. Influence of HLA-DRB1 genes and the shared epitope on genetic susceptibility to rheumatoid arthritis in Taiwanese. J Rheumatol 2007; 34: 674–680.
Google Scholar | Medline33. Lee, HS, Lee, KW, Song, GG, et al. Increased susceptibility to rheumatoid arthritis in Koreans heterozygous for HLA-DRB1*0405 and *0901. Arthritis Rheum 2004; 50: 3468–3475.
Google Scholar | Crossref | Medline34. Greenberg, JD, Kremer, JM, Curtis, JR, et al; CORRONA Investigators . Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 576–582.
Google Scholar | Crossref | Medline | ISI35. Nurmohamed, M, Bao, Y, Signorovitch, J, et al. Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open 2015; 1: e000080.
Google Scholar | Crossref | Medline36. Desai, RJ, Rao, JK, Hansen, RA, et al. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. J Rheumatol 2014; 41: 2129–2136.
Google Scholar | Crossref | Medline37. Kirkham, BW, Wasko, MC, Hsia, EC, et al. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis 2014; 73: 161–169.
Google Scholar | Crossref | Medline38. Heslinga, SC, Konings, TC, van der Horst-Bruinsma, IE, et al. The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis. Biologics 2018; 12: 143–149.
Google Scholar | Medline39. Zhang, J, Xie, F, Yun, H, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75: 1813–1818.
Google Scholar | Crossref | Medline40. Jin, Y, Kang, EH, Brill, G, et al. Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease. J Rheumatol 2018; 45: 1240–1248.
Google Scholar | Crossref | Medline41. Kang, EH, Jin, Y, Brill, G, et al. Comparative cardiovascular risk of abatacept and tumor necrosis factor inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus: a multidatabase cohort study. J Am Heart Assoc 2018; 7: e007393.
Google Scholar | Crossref42. Afek, A, Harats, D, Roth, A, et al. Evidence for the involvement of T cell costimulation through the B-7/CD28 pathway in atherosclerotic plaques from apolipoprotein E knockout mice. Exp Mol Pathol 2004; 76: 219–223.
Google Scholar | Crossref | Medline43. Dopheide, JF, Sester, U, Schlitt, A, et al. Monocyte-derived dendritic cells of patients with coronary artery disease show an increased expression of costimulatory molecules CD40, CD80 and CD86 in vitro. Coron Artery Dis 2007; 18: 523–531.
Google Scholar | Crossref | Medline44. Müller, A, Mu, L, Meletta, R, et al. Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting costimulatory molecules. Int J Cardiol 2014; 174: 503–515.
Google Scholar | Crossref | Medline45. Hermans, MPJ, van der Velden, D, Montero Cabezas, JM, et al. Long-term mortality in patients with ST-segment elevation myocardial infarction is associated with anti-citrullinated protein antibodies. Int J Cardiol 2017; 240: 20–24.
Google Scholar | Crossref | Medline46. Garcia-Gomez, C, Martin-Martinez, MA, Castañeda, S, et al; CARMA Project Collaborative Group . Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: results from the CARdiovascular in rheuMAtology study project. J Clin Lipidol 2017; 11: 749–756.e3.
Google Scholar |